Media Room

Latest News Releases

Nov 9, 2018

Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting....

Nov 7, 2018

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018. Cash and investments in marketable securities at September 30, 2018 were...

Nov 6, 2018

New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers

Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (NYSE:PFE) to evaluate several combination regimens in multiple cancer...

Multimedia Libraries

Broadcast Video

Image Gallery

Media Contacts

Dan Budwick
Pure Communications, Inc.
Media@purecommunications...

Follow @NektarNews

Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide